For any drug candidate to be approved by the U.S. Food and Drug Administration, it must meet strict standards for safety and efficacy. While the field of nuclear medicine is over 100 years old, traditional methods such as external beams or systematic administration have rarely met these standards or have limited application. Ligand-targeted therapy and diagnostics, or “theranostics,” has emerged in the past several decades as an exciting field that offers new possibilities to design drugs that are both safe and effective. When applied to nuclear medicine, the field of ligand-targeted radioactive theranostics is younger still, with many critical lessons being discovered and applied currently. This dissertation outlines the necessary principles of radioactive theranostic drug design, then demonstrates the application of several more recent techniques to improve both the efficacy and safety of radioactive theranostics targeting two high priority oncological targets: fibroblast activation protein alpha and folate receptor.
| Identifer | oai:union.ndltd.org:purdue.edu/oai:figshare.com:article/15077778 |
| Date | 29 July 2021 |
| Creators | Spencer D Lindeman (11205204) |
| Source Sets | Purdue University |
| Detected Language | English |
| Type | Text, Thesis |
| Rights | In Copyright |
| Relation | https://figshare.com/articles/thesis/DESIGN_SYNTHESIS_AND_PRECLINICAL_EVALUATION_OF_LIGAND-TARGETED_CONJUGATES_FOR_CANCER_RADIOTHERANOSTICS/15077778 |
Page generated in 0.0016 seconds